Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
- Associated Therapies
- -
Advancements in CLL: CAR T, BTK Inhibitors and Personalized Medicine
BTK inhibitors and BCL-2 inhibitors have replaced chemotherapy in CLL treatment, with personalized medicine like mutation and MRD testing guiding care. CAR T-cell therapy and pirtobrutinib offer new options for resistant patients. Future research aims for a cure, explores bispecific T-cell engagers, and uses MRD testing for decision-making.
Gazyva/Gazyvaro Shows Improved Complete Renal Response Among Patients with Lupus Nephritis
The Phase III REGENCY trial showed Gazyva/Gazyvaro (obinutuzumab) plus standard therapy achieved higher complete renal response (CRR) in lupus nephritis patients compared to standard therapy alone. The trial also observed significant CRR with reduced corticosteroid use and improved proteinuric response. Gazyva/Gazyvaro could offer a new treatment option for lupus nephritis, potentially delaying end-stage kidney disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath